# Julien Hadoux

Source: https://onco.cc/people/julien-hadoux/  
OnCo record `julien-hadoux` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paris endocrine oncologist who was lead author of LIBRETTO-531, the trial that showed the selective RET inhibitor selpercatinib beats older kinase inhibitors as first treatment for advanced medullary thyroid cancer.

## Summary

Julien Hadoux is an endocrine oncologist at Gustave Roussy who treats thyroid and neuroendocrine cancers. He was first author of the 2023 New England Journal of Medicine report of LIBRETTO-531, the phase 3 trial in which selpercatinib lengthened progression-free survival compared with cabozantinib or vandetanib in untreated RET-mutant advanced medullary thyroid cancer, establishing the selective RET inhibitor as first-line therapy.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: thyroid; targeted-therapy; trialist
- Role: Endocrine oncologist, Gustave Roussy
- Specialisms: Medullary thyroid cancer; RET inhibitors; Neuroendocrine tumours

## Connected records

- cancers: [Medullary thyroid cancer](https://onco.cc/cancers/medullary-thyroid-cancer/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- institutions: [Gustave Roussy](https://onco.cc/institutions/gustave-roussy/)
- key papers: [LIBRETTO-531: selpercatinib versus cabozantinib or vandetanib in advanced RET-mutant medullary thyroid cancer](https://onco.cc/key-papers/paper-libretto-531-nejm-2023/)

---
JSON: https://onco.cc/api/v1/entities/julien-hadoux.json